Dipexium Pharmaceuticals Presents Locilex® Microbiology Data at ICAAC/ICC 2015 Conference

NEW YORK, Sept. 21, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex® microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.

In a poster presentation entitled "In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials," investigators stated that pexiganan, the active pharmaceutical ingredient in Locilex®, demonstrated potent in vitro activity against a broad spectrum of Gram-positive and Gram-negative bacteria selected as having elevated MIC₉₀ (minimum inhibitory concentration) values to topical antibiotics, including bacitracin, polymyxin B, neomycin, mupirocin, retapamulin, and fusidic acid. Pexiganan also demonstrated activity against gentamicin-susceptible and gentamicin-resistant isolates. A copy of the ICAAC/ICC poster presentation can be found on Dipexium's website at www.dipexiumpharmaceuticals.com/locilex/key-publications.

Pexiganan's MIC₉₀ values for each of the organism groups studied, including difficult-to-treat Gram-positive staphylococci, beta-hemolytic streptococci, enterococci, viridans group streptococci, as well as Gram-negative Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, and Acinetobacter baumannii were below the concentration of pexiganan in Locilex®'s topical cream formulation, indicating that the concentration of pexiganan in the current commercial scale batches should be sufficient to inhibit most infecting organisms in superficial skin and wound infections amenable to treatment with a topical antimicrobial. The authors also noted a lack of cross-resistance between pexiganan and the topical antimicrobials tested, citing, for example, that against all Staphylococcus aureus isolates tested, pexiganan MIC₅₀ and MIC₉₀ values were 16 µg/mL.

Robert K. Flamm, Ph.D., Director, Antimicrobial Development at JMI Laboratories, and principal investigator for the study, said, "JMI Laboratories has now completed four microbiology studies of pexiganan on behalf of Dipexium. Data from these studies consistently demonstrate pexiganan's potent bactericidal activity against a broad spectrum of bacteria, including those highly resistant to currently marketed antimicrobials, whether systemic or topical. In the current environment of emerging multi-drug resistant bacteria, pexiganan is a potentially important therapeutic agent in the treatment of superficial skin and wound infections."

"No antibiotic is currently approved in the US or European Union for the treatment of mild infections of diabetic foot ulcers (Mild DFI)," stated David P. Luci, President & Chief Executive Officer of Dipexium. "These pexiganan microbiology data provide additional strong support for the rationale behind our on-going pivotal Phase 3 program in patients with Mild DFI, as well as Locilex®'s potential clinical development in the treatment of other skin and wound infections."

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (Website - http://www.dipexiumpharmaceuticals.com) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]

Investor Relations Contact:

Donna L. LaVoie or Kristina Coppola
LaVoie Health Science
617-374-8800 X107/105
[email protected]

© 2015 Dipexium Pharmaceuticals, Inc.  All rights reserved.

SOURCE Dipexium Pharmaceuticals, Inc.

Related Links

http://www.dipexiumpharmaceuticals.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED